Altimmune, Inc. (ALT)
| Market Cap | 626.05M |
| Revenue (ttm) | 3.48M |
| Net Income (ttm) | -96.94M |
| Shares Out | 49.03M |
| EPS (ttm) | -2.39 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,266,535 |
| Open | 12.64 |
| Previous Close | 12.62 |
| Day's Range | 12.58 - 13.41 |
| 52-Week Range | 3.83 - 23.49 |
| Beta | 0.18 |
| Analysts | Buy |
| Price Target | 29.43 (+130.5%) |
| Earnings Date | Nov 7, 2022 |
About ALT
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known... [Read more...]
Financial Performance
In 2021, Altimmune's revenue was $4.41 million, a decrease of -46.12% compared to the previous year's $8.19 million. Losses were -$97.09 million, 98.0% more than in 2020.
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for ALT stock is "Buy." The 12-month stock price forecast is 29.43, which is an increase of 130.46% from the latest price.
News
Altimmune Announces First Dosing of All Subjects in Phase 2 MOMENTUM Trial of Pemvidutide in Subjects with Obesity or...
Twenty-four week interim analysis on approximately 160 subjects planned for Q1 2023 Twenty-four week interim analysis on approximately 160 subjects planned for Q1 2023
Altimmune's (ALT) Data From NASH Study Fail to Impress Investors
Altimmune (ALT) reports positive top-line results from its 12-week phase I study evaluating pemvidutide in patients with non-alcoholic fatty liver disease. The results fail to impress investors.
Altimune (ALT) Stock Plummets 33% Despite Positive Clinical Data
Source: Shutterstock Altimune (NASDAQ: ALT ) stock is falling hard on Wednesday even after reporting positive results from a Phase 1b clinical trial this morning. That clinical trial concerns the use of...
Altimmune's stock falls 44% after sharing data from trial for liver disease treatment
Shares of Altimmune Inc. ALT, -0.39% tumbled 44.4% in premarket trading on Wednesday after the company shared new data from an early-stage clinical trial for its experimental treatment for non-alcoholic...
Altimmune Announces Significant Reductions in Liver Fat Content and Body Weight in 12-Week Phase 1b Clinical Trial of...
GAITHERSBURG, Md., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced positive topline results from its 12-week Phase 1b study ...
Altimmune, Inc. (ALT) Reports Q2 Loss, Misses Revenue Estimates
Altimmune, Inc. (ALT) delivered earnings and revenue surprises of 6.67% and 99.54%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
7 Biotech Stocks to Buy for Q3
These biotech stocks could be good buys due for a few reasons, including great R&D pipelines and treatments with promising market potential. The post 7 Biotech Stocks to Buy for Q3 appeared first on Inv...
Here's Why Altimmune, Inc. (ALT) is a Great Momentum Stock to Buy
Does Altimmune, Inc. (ALT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Is Altimmune (ALT) Stock Outpacing Its Medical Peers This Year?
Here is how Altimmune, Inc. (ALT) and argenex (ARGX) have performed compared to their sector so far this year.
Is Altimmune (ALT) Outperforming Other Medical Stocks This Year?
Here is how Altimmune, Inc. (ALT) and Chinook Therapeutics (KDNY) have performed compared to their sector so far this year.
Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at Upcoming EASL International Liver Congress™ on ...
Presentation to be highlighted in the Best of International Liver Congress Presentation to be highlighted in the Best of International Liver Congress
Has Altimmune (ALT) Outpaced Other Medical Stocks This Year?
Here is how Altimmune, Inc. (ALT) and Sensus Healthcare, Inc. (SRTS) have performed compared to their sector so far this year.
Wall Street Analysts Think Altimmune, Inc. (ALT) Could Surge 352%: Read This Before Placing a Bet
The mean of analysts' price targets for Altimmune, Inc. (ALT) points to a 352.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among an...
Altimmune to Participate at Two Upcoming Investor Conferences
GAITHERSBURG, Md., June 03, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company's management team will partici...
Altimmune to Present Pemvidutide Clinical Data at Upcoming American Diabetes Association Scientific Sessions June 6, ...
GAITHERSBURG, Md., May 31, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Samuel Klein, William H. Danforth Professor of Med...
Wall Street Analysts See a 426% Upside in Altimmune, Inc. (ALT): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 425.9% in Altimmune, Inc. (ALT). While the effectiveness of this highly sought-after metric is questionable, the ...
Altimmune to Present Pemvidutide Clinical Data at Upcoming Global NASH Congress May 27, 2022
GAITHERSBURG, Md., May 20, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer at Altimmune,...
Altimmune to Present at Upcoming Investor Conferences
GAITHERSBURG, Md., May 16, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company's management team will particip...
Altimmune, Inc. (ALT) Reports Q1 Loss, Misses Revenue Estimates
Altimmune, Inc. (ALT) delivered earnings and revenue surprises of 22.81% and 98.45%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Altimmune Announces Initiation of 48-week Phase 2 MOMENTUM Trial of Pemvidutide in Obesity
The Company also announces completion of enrollment in 12-week, Phase 1b trial of pemvidutide in subjects with non-alcoholic fatty liver disease (NAFLD) The Company also announces completion of enrollme...
Altimmune, Inc. (ALT) Reports Q4 Loss, Tops Revenue Estimates
Altimmune, Inc. (ALT) delivered earnings and revenue surprises of 23.44% and 2,145.21%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Altimmune Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update
Data readouts from multiple clinical trials expected during the next 6 to 12 months
Altimmune to Report Fourth Quarter and Full Year 2021 Financial Results on March 15, 2022
GAITHERSBURG, Md., March 08, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its fourth quarter and full year 2021...
Analysts Estimate Altimmune, Inc. (ALT) to Report a Decline in Earnings: What to Look Out for
Altimmune, Inc. (ALT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Altimmune's Mid-Stage Pemvidutide Study Cleared By FDA For Obesity
The FDA has cleared Altimmune Inc's ALT Investigational New Drug (IND) application for its Phase 2 trial of pemvidutide for obesity. [ALERT] Nic Chahine shares his Bear Market Beating options trading s...